BioStock: Stayble presents additional positive interim data

Just before Easter, Stayble Therapeutics presented positive interim data from 100 patients in the phase IIb study with STA363 for the treatment of degenerative disc disease. The interim analysis shows that the injection treatment is safe and that the pain measurements have a low dispersion, which is beneficial for the final data read-out at the end of the year. BioStock contacted the company’s CSO Anders Lehmann to learn more about the progress of the study.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/04/stayble-presents-additional-positive-interim-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se